Global target-to-clinic accelerator providing a hybrid AI/ML platform for preclinical drug discovery and early development — target identification, virtual screening, nonclinical/clinical pharmacology, chemical liability assessment, toxicology, and IP landscape/competitive intelligence. De-risks candidate selection to accelerate in silico-to-first-in-human transition and sets up/manages seed and Series A R&D programs for financial investors and strategic partners.